SPOTLIGHT
Regimen
- Experimental
- zolbetuximab + mFOLFOX6
- Control
- placebo + mFOLFOX6
Population
CLDN18.2-positive (>=75% cells IHC 2+/3+) HER2-negative advanced gastric/GEJ cancer as first-line therapy
Key finding
mPFS 10.61 vs 8.67 mo (HR 0.75, 95% CI 0.60-0.94, p=0.0066); mOS 18.23 vs 15.54 mo (HR 0.75, 95% CI 0.60-0.94, p=0.0053)
Source: PMID 37068504
Timeline
Guideline citations
- NCCN GASTRIC (p.30)
- CSCO GASTRIC 2025 (p.31)⚠️ OCR source